Editas Q1 2021 Earnings Report
Key Takeaways
Editas Medicine reported a net loss of $56.7 million for the first quarter of 2021. The company is progressing clinical trials for EDIT-101 and EDIT-301 and appointed Mark S. Shearman as Chief Scientific Officer. The company's cash, cash equivalents, and marketable securities totaled $723.2 million as of March 31, 2021.
Advanced BRILLIANCE trial of EDIT-101 for LCA10, with clinical data expected by year-end.
RUBY trial of EDIT-301 for sickle cell disease is active and recruiting patients.
Preclinical ocular data presented at ARVO supports in vivo gene editing for USH2A and RP4.
Appointed Mark S. Shearman, Ph.D., as Chief Scientific Officer.
Editas
Editas
Forward Guidance
Editas Medicine is on track to dose the first patient in the RUBY trial by year-end and file an IND for EDIT-301 for the treatment of beta-thalassemia by the end of 2021. Initial clinical data for EDIT-101 is expected by year-end.
Positive Outlook
- On track to dose first patient in RUBY trial by year-end.
- On track to file IND for EDIT-301 for Beta-Thalassemia by year-end.
- Initial clinical data for EDIT-101 expected by year-end.
- Continuing to dose patients in the second cohort of the BRILLIANCE trial.
- Expects to declare a development candidate for its RP4 program by the end of 2021.